VIDEO: ACC/AHA atherosclerotic CVD risk score ‘good first step’ to improve chest pain evaluation in ED

CHICAGO — Kareem Niazi, MD, of Northwell Health in Great Neck, NY, highlights the predictive power of the American College of Cardiology/American Heart Association atherosclerotic CVD risk estimator in evaluating patients presenting to the ED with chest pain.

After providing background on resource utilization vs. actual ACS in this setting, he offers investigator insight from research studying approaches to improve the assessment of low- to intermediate-risk populations.

He underscores the clinical value of coronary CTA, pointing to results from the ROMICAT II trial, and details specific results based on ASCVD score.

“There are not good risk stratification tools that have been widely adopted by ED physicians at this time,” Niazi said. “It is a good first step showing that this risk score can be useful as another data point for ED doctors.”

Finally, he emphasizes how the findings intersect with important comments from Kim Allan Williams Sr., MD, FACC, past president of the ACC, and David B. Nash, MD, MBA, dean of the population health department at Thomas Jefferson University in Philadelphia.

For more information:

Niazi K, et al. Presentation 1132-036, Poster Contributions, Assessing the Patient With Chest Pain: Diagnostic Tools and Management Protocols. Presented at: American College of Cardiology Scientific Session; April 2-4, 2016; Chicago.

Niazi K, et al. J Am Coll Cardiol. 2016; doi:10.1016/S0735-1097(16)30527-7.